The slip
PARKINSON RECEIPTno. 16959
01 Nov 2026, 04:08 UTCmicroglia, braak
predictionSPECC1 in microglia tracks Braak Lewy-body stage
registered1f3c361c36aed11f
discovery+0.02 p=0.964 n=9
replication-0.56 p=0.118 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.02, p 0.964)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT8f10d7f76097d137050dc205…
follows 196ae83fc399…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 16959: SPECC1 in microglia, braak
- power
- full sample -0.28 (p 0.254, n 18), 95% CI -0.66 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.30 (p 0.232, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.22, sign flips 0; without severely affected donors -0.28 (p 0.254, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.64 (p 0.0045, n 18) vs -0.28 in microglia. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SPECC1 in microglia.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SPECC1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 1.4e-4)